{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:51:01Z","timestamp":1778673061423,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017160","name":"Beni Suef University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017160","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Multiple myeloma (MM) is a blood cancer that, unfortunately, has a high morbidity and mortality rate. The VMP regimen, which includes bortezomib (BOR), melphalan (MEL), and prednisolone (PRD), is a safe and effective salvage regimen for refractory or relapsed MM. Up to now, there is no established analytical method to determine the VMP regimen, nor has any study investigated the kinetic interactions among its components, thereby highlighting the need for further clinical investigation. In light of this, an environmentally friendly, fast, sensitive, and precise LC-MS\/MS method was established to determine bortezomib, melphalan, prednisolone, and sildenafil (an internal standard) simultaneously as part of the in vivo pharmacokinetics research carried out on rats. The established LC-MS\/MS method was applied using a mobile phase composed of a mixture of methanol: 0.1% aqueous solution of formic acid and a ZORBAX Eclipse Plus C18 column (4.6\u00a0mm \u00d7 150\u00a0mm, 5\u00a0\u03bcm) as a stationary phase. The cited drugs were ionized through positive ionization and detected using multi-reaction monitoring (MRM) mode with the following precursor\u2192product transitions: m\/z 367.3\u2192226.3 for BOR, m\/z 305.0\u2192168.2 for MEL, m\/z 545.0\u2192147.5 for PRD, and m\/z 475.3\u2192283.4 for SIL. Following FDA guidelines, the developed method was validated and showed acceptable ranges. Subsequently, it was employed in an in vivo investigation using rats, where the quantitative assessment of each drug was performed following both single and combined treatment. This allowed for the investigation of potential drug-drug interactions and the calculation of all pharmacokinetic parameters to monitor the therapeutic effects of those medications. To ensure the safety and environmental friendliness of the developed method, four assessment tools were applied: the assessment of green profile (AGP), blue applicability grade index (BAGI), analytical greenness metric for sample preparation (AGREEprep), and green analytical procedure index (GAPI).<\/jats:p>","DOI":"10.1038\/s41598-025-15078-6","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T18:38:45Z","timestamp":1755196725000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Novel environmental and sustainable approach for concurrent assay of antineoplastics in VMP regimen with a comprehensive Pharmacokinetic study"],"prefix":"10.1038","volume":"15","author":[{"given":"Marco","family":"M. Z. Sharkawi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noha","family":"H. Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norhan","family":"R. Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimaa","family":"S. Zaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loah","family":"R. Hemeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"15078_CR1","first-page":"3","volume":"9","author":"SA Padala","year":"2021","unstructured":"Padala, S. A. et al. Epidemiology, staging, and management of multiple myeloma. Med. Sci. 9, 3 (2021).","journal-title":"Med. Sci."},{"key":"15078_CR2","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1200\/JCO.1988.6.11.1768","volume":"6","author":"G Sarosy","year":"1988","unstructured":"Sarosy, G., Leyland-Jones, B., Soochan, P. & Cheson, B. The systemic administration of intravenous Melphalan. J. Clin. Oncol. 6, 1768\u20131782 (1988).","journal-title":"J. Clin. Oncol."},{"key":"15078_CR3","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.3390\/jcm10091841","volume":"10","author":"A Poczta","year":"2021","unstructured":"Poczta, A., Rogalska, A. & Marczak, A. Treatment of multiple myeloma and the role of Melphalan in the era of modern therapies\u2014Current research and clinical approaches. J. Clin. Med. 10, 1841 (2021).","journal-title":"J. Clin. Med."},{"key":"15078_CR4","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1586\/14737140.7.7.945","volume":"7","author":"P Falco","year":"2007","unstructured":"Falco, P. et al. Melphalan and its role in the management of patients with multiple myeloma. Expert Rev. Anticancer Ther. 7, 945\u2013957 (2007).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"15078_CR5","doi-asserted-by":"crossref","unstructured":"Gupta, V. et al. Efficacy of prednisone in refractory multiple myeloma and measurement of glucocorticoid receptors: A Southwest Oncology Group study, Investigational new drugs, 12 121\u2013128. (1994).","DOI":"10.1007\/BF00874441"},{"key":"15078_CR6","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.beha.2007.09.003","volume":"20","author":"MV Mateos","year":"2007","unstructured":"Mateos, M. V., San, J. F. & Miguel Bortezomib in multiple myeloma. Best Pract. Res. Clin. Haematol. 20, 701\u2013715 (2007).","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"15078_CR7","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","volume":"11","author":"MV Mateos","year":"2010","unstructured":"Mateos, M. V. et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 11, 934\u2013941 (2010).","journal-title":"Lancet Oncol."},{"key":"15078_CR8","doi-asserted-by":"publisher","first-page":"025","DOI":"10.1310\/hpj5001-25","volume":"50","author":"S Bryant","year":"2015","unstructured":"Bryant, S., Solimando, D. A. Jr & Waddell, J. A. Bortezomib, melphalan, and prednisone (VMP) regimen for multiple myeloma. Hosp. Pharm. 50, 025\u2013030 (2015).","journal-title":"Hosp. Pharm."},{"key":"15078_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10337-022-04232-1","volume":"86","author":"MM Sharkawi","year":"2023","unstructured":"Sharkawi, M. M., Mohamed, N. R., El-Saadi, M. T. & Amin, N. H. FDA-validated ecofriendly chromatographic methods for simultaneous determination of gemcitabine and sorafenib: applications to pharmacokinetics. Chromatographia 86, 109\u2013123 (2023).","journal-title":"Chromatographia"},{"key":"15078_CR10","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1039\/D3AY00081H","volume":"15","author":"MM Sharkawi","year":"2023","unstructured":"Sharkawi, M. M., Mohamed, N. R., El-Saadi, M. T. & Amin, N. H. Ecofriendly LC-MS\/MS and TLC-densitometric methods for simultaneous quantitative assay and monitoring of BEGEV regimen, in vivo Pharmacokinetic study application. Anal. Methods. 15, 1016\u20131027 (2023).","journal-title":"Anal. Methods"},{"key":"15078_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.22270\/jddt.v13i6.5889","volume":"13","author":"B Srikanth","year":"2023","unstructured":"Srikanth, B. et al. Method development and validation for quantitative Estimation of bortezomib in its bulk and pharmaceutical formulation. J. Drug Delivery Ther. 13, 145\u2013151 (2023).","journal-title":"J. Drug Delivery Ther."},{"key":"15078_CR12","doi-asserted-by":"publisher","first-page":"035","DOI":"10.7324\/JAPS.2017.70105","volume":"7","author":"B Chandramowli","year":"2017","unstructured":"Chandramowli, B. & Rajkamal, B. B. A validated LC-MS\/MS method for the Estimation of bortezomib and bortezomib D3 (IS) in human plasma with protein precipitation and SPE filter cartridges. J. Appl. Pharm. Sci. 7, 035\u2013041 (2017).","journal-title":"J. Appl. Pharm. Sci."},{"key":"15078_CR13","doi-asserted-by":"publisher","first-page":"122905","DOI":"10.1016\/j.jchromb.2021.122905","volume":"1181","author":"ZX Guo","year":"2021","unstructured":"Guo, Z. X., Yang, F., van den Anker, J. N., Zheng, Y. & Zhao, W. A simplified method for bortezomib determination using dried blood spots in combination with liquid chromatography\/tandem mass spectrometry. J. Chromatogr. B. 1181, 122905 (2021).","journal-title":"J. Chromatogr. B"},{"key":"15078_CR14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jchromb.2013.01.037","volume":"926","author":"I Andriamanana","year":"2013","unstructured":"Andriamanana, I., Gana, I., Duretz, B. & Hulin, A. Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, Sunitinib and Vandetanib in human plasma using LC\/MS\/MS. J. Chromatogr. B. 926, 83\u201391 (2013).","journal-title":"J. Chromatogr. B"},{"key":"15078_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/BF00258477","volume":"5","author":"IAK Taha","year":"1981","unstructured":"Taha, I. A. K., Ahmad, R. A. J. & Rogers, H. J. Melphalan Estimation by quantitative thin-layer chromatography: observations on Melphalan hydrolysis in vitro and pharmacokinetics in rabbits. Cancer Chemother. Pharmacol. 5, 181\u2013184 (1981).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"15078_CR16","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00280-019-03786-6","volume":"83","author":"L Huang","year":"2019","unstructured":"Huang, L. et al. Long-Boyle, determination of Melphalan in human plasma by UPLC\u2013UV method. Cancer Chemother. Pharmacol. 83, 905\u2013910 (2019).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"15078_CR17","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/BF00257364","volume":"21","author":"HK Osterheld","year":"1988","unstructured":"Osterheld, H. K. et al. A sensitive high-performance liquid chromatographic assay for Melphalan and its hydrolysis products in blood and plasma. Cancer Chemother. Pharmacol. 21, 156\u2013162 (1988).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"15078_CR18","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1007\/BF02493133","volume":"52","author":"I Davies","year":"2000","unstructured":"Davies, I., Allanson, J. & Causon, R. Rapid determination of the anti-cancer drug Melphalan (AlkeranTM) in human serum and plasma by automated solid phase extraction and liquid chromatography tandem mass spectrometry. Chromatographia 52, S92\u2013S97 (2000).","journal-title":"Chromatographia"},{"key":"15078_CR19","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/rcm.6515","volume":"27","author":"J Boschmans","year":"2013","unstructured":"Boschmans, J., de Bruijn, E., Van Schil, P. & Lemi\u00e8re, F. Analysis of novel Melphalan hydrolysis products formed under isolated lung perfusion conditions using liquid chromatography\/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 27, 835\u2013841 (2013).","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"15078_CR20","doi-asserted-by":"publisher","first-page":"123698","DOI":"10.1016\/j.jchromb.2023.123698","volume":"1222","author":"S Li","year":"2023","unstructured":"Li, S., Wang, Y., Zhang, B. & Cai, H. A rapid and sensitive LC-MS\/MS method for simultaneous determination of Melphalan and its monohydroxy and dihydroxy metabolites in human plasma. J. Chromatogr. B. 1222, 123698 (2023).","journal-title":"J. Chromatogr. B"},{"key":"15078_CR21","doi-asserted-by":"publisher","first-page":"e5343","DOI":"10.1002\/bmc.5343","volume":"36","author":"NS Abdelhamid","year":"2022","unstructured":"Abdelhamid, N. S., Magdy, M. A., Anwar, B. H. & Farid, N. F. US FDA\u2013validated TLC method with four greenness assessment evaluations for simultaneous determination of prednisolone and Esomeprazole in spiked human plasma. Biomed. Chromatogr. 36, e5343 (2022).","journal-title":"Biomed. Chromatogr."},{"key":"15078_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/chromsci\/43.4.201","volume":"43","author":"MN Gai","year":"2005","unstructured":"Gai, M. N. et al. Determination of prednisolone and prednisone in plasma, whole blood, urine, and bound-to-plasma proteins by high-performance liquid chromatography. J. Chromatogr. Sci. 43, 201\u2013206 (2005).","journal-title":"J. Chromatogr. Sci."},{"key":"15078_CR23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/00007691-200104000-00012","volume":"23","author":"O Majid","year":"2001","unstructured":"Majid, O., Akhlaghi, F., Lee, T., Holt, D. W. & Trull, A. Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. Ther. Drug Monit. 23, 163\u2013168 (2001).","journal-title":"Ther. Drug Monit."},{"key":"15078_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1258\/0004563053492810","volume":"42","author":"L Owen","year":"2005","unstructured":"Owen, L., Gillingwater, S. & Keevil, B. Prednisolone measurement in human serum using liquid chromatography tandem mass spectrometry. Ann. Clin. Biochem. 42, 105\u2013111 (2005).","journal-title":"Ann. Clin. Biochem."},{"key":"15078_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1530\/EC-13-0023","volume":"2","author":"P Methlie","year":"2013","unstructured":"Methlie, P. et al. Multisteroid LC\u2013MS\/MS assay for glucocorticoids and androgens and its application in addison\u2019s disease. Endocr. Connections. 2, 125\u2013136 (2013).","journal-title":"Endocr. Connections"},{"key":"15078_CR26","unstructured":"Raynie, D. & Driver, J. Green assessment of chemical methods 13th Green Chem Conf. USA (2009)."},{"key":"15078_CR27","doi-asserted-by":"publisher","first-page":"7598","DOI":"10.1039\/D3GC02347H","volume":"25","author":"N Manousi","year":"2023","unstructured":"Manousi, N., Wojnowski, W., P\u0142otka-Wasylka, J. & Samanidou, V. Blue applicability grade index (BAGI) and software: a new tool for the evaluation of method practicality. Green Chem. 25, 7598\u20137604 (2023).","journal-title":"Green Chem."},{"key":"15078_CR28","doi-asserted-by":"publisher","first-page":"116553","DOI":"10.1016\/j.trac.2022.116553","volume":"149","author":"W Wojnowski","year":"2022","unstructured":"Wojnowski, W., Tobiszewski, M., Pena-Pereira, F. & Psillakis, E. AGREEprep\u2013analytical greenness metric for sample Preparation. TRAC Trends Anal. Chem. 149, 116553 (2022).","journal-title":"TRAC Trends Anal. Chem."},{"key":"15078_CR29","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.talanta.2018.01.013","volume":"181","author":"J P\u0142otka-Wasylka","year":"2018","unstructured":"P\u0142otka-Wasylka, J. A new tool for the evaluation of the analytical procedure: green analytical procedure index. Talanta 181, 204\u2013209 (2018).","journal-title":"Talanta"},{"key":"15078_CR30","unstructured":"Janet, C. et al. Guide for the Care and Use of Laboratory Animals: Eighth Edition, (2011)."},{"key":"15078_CR31","unstructured":"U.S. Department of Health and Human Services. Food and Drug Administration Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), Bioanalytical method validation guidance for industry, (2013)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15078-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15078-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15078-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T03:10:55Z","timestamp":1757387455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15078-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15078"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-15078-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article contains studies involving animals and is reported in accordance with ARRIVE guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors agree to participate in the published version of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"29894"}}